| Literature DB >> 35635281 |
Natasha Y Sheikhan1,2, Lisa D Hawke1,3, Clement Ma1,2, Darren Courtney1,3, Peter Szatmari1,3, Kristin Cleverley1,3,4, Aristotle Voineskos1,3, Amy Cheung5, Joanna Henderson1,3.
Abstract
BACKGROUND: Youth mental health appears to have been negatively impacted by the COVID-19 pandemic. The impact on substance use is less clear, as is the impact on subgroups of youth, including those with pre-existing mental health or substance use challenges.Entities:
Keywords: COVID-19; adolescence; longitudinal study; mental disorders; mental health; students; substance use disorders; young adults; youth
Mesh:
Year: 2022 PMID: 35635281 PMCID: PMC9157274 DOI: 10.1177/07067437221097906
Source DB: PubMed Journal: Can J Psychiatry ISSN: 0706-7437 Impact factor: 5.321
Figure 1.Sample flow diagram to display study selection for the pre-pandemic sample. Diagram includes source cohorts, screening process, and the final study sample. YCI represents YouthCan IMPACT cohort, EIPSS represents the Early Identification of Psychosis Spectrum Symptoms cohort, and YACDS represents the Youth Addictions and Concurrent Disorder Service cohort.
Demographic and Clinical Characteristics at T1 (n = 168).
| Frequency (%) | ||
|---|---|---|
| Gender | Man/boy | 51 (30.4%) |
| Woman/girl | 108 (64.3%) | |
| Transgender or non-binary | 9 (5.4%) | |
| Ethnic origin | Caucasian | 91 (54.2%) |
| Asian (East) | 10 (6.0%) | |
| Asian (South and South East) | 12 (7.2%) | |
| Black (African and Caribbean) | 15 (8.9%) | |
| Mixed heritage | 22 (13.1%) | |
| Latin American | 5 (3.0%) | |
| Indigenous | 3 (1.8%) | |
| Another background | 10 (6.0%) | |
| Born in Canada | 143 (85.1%) | |
| First language English | 159 (95.2%) | |
| Student | 118 (70.2%) | |
| Not in employment, education, or training | 22 (13.3%) | |
| Living situation | Own apartment/home | 12 (7.2%) |
| With parents or other family members | 132 (79.0%) | |
| With friends/peers | 10 (6.0%) | |
| Precarious housing | 13 (7.8%) | |
| Legal system involvement | 38 (22.6%) | |
| Receiving government support | 29 (17.4%) | |
| GAIN Short Screener (past month diagnosis)a | Internalizing disorder | 108 (64.3%) |
| Externalizing disorder | 59 (35.1%) | |
| Substance use disorder | 45 (26.8%) | |
| Crime/violence | 2 (1.2%) | |
| Total screener | 147 (87.5%) |
aGAIN Short Screener scores are used here to determine the proportion of participants who met the criteria for a high likelihood of a diagnosis in the past month.
Mental Health and Substance use in Youth Across 8 Timepoints. Estimated Marginal Means (and 95% Confidence Intervals) and Type III Test p-Values of the Main Effects of Time are Reported.
| Outcomes | T1 (n = 168) | T2 (n = 160) | T3 (n = 121) | T4 (n = 103) | T5 (n = 101) | T6 (n = 94) | T7 (n = 92) | T8 (n = 109) | |
|---|---|---|---|---|---|---|---|---|---|
| Estimated Marginal Means (95% CI) from Linear Mixed Models | P-value | ||||||||
|
| 3.28 | 3.25 | 3.24 | 3.29 | 3.09 | 3.18 | 3.18 | 3.15 | 0.97 |
| (2.95–3.61) | (2.96–3.53) | (2.93–3.55) | (2.96–3.62) | (2.76–3.42) | (2.84–3.52) | (2.83–3.53) | (2.82–3.48) | ||
|
| 1.83 | 2.06 | 2.03 | 1.85 | 2.03 | 2.16 | 2.18 | 2.24 | 0.21 |
| (1.57–2.09) | (1.82–2.29) | (1.77–2.29) | (1.57–2.12) | (1.75–2.31) | (1.87–2.44) | (1.89–2.48) | (1.96–2.52) | ||
| Estimated Proportion of Participants with Moderate to High Likelihood of Clinical Diagnosis | P-value | ||||||||
|
| 0.48 | 0.42 | 0.37 | 0.50 | 0.34 | 0.35 | 0.27 | 0.31 | 0.02 |
| (0.40–0.57) | (0.33–0.51) | (0.28–0.46)a | (0.39–0.61) | (0.25–0.45)a | (0.25–0.46)a | (0.19–0.38)a | (0.22–0.41)a | ||
Legend: Symbol a represents statistical significance for the pairwise contrast between each pandemic timepoint vs. T1.
Notes: Each model used T1 as the reference group and adjusted for age and source cohort. Data was collected from April 2018 to October 2019 (T1), April 2020 (T2), June 2020 (T3), August 2020 (T4), October 2020 (T5), December 2020 (T6), February 2021 (T7), and April 2021 (T8).
Interactions Between Sociodemographic Characteristics and Time on Mental Health and Substance use. Estimated Marginal Means (95% Confidence Intervals) and Estimated Proportion of Participants with Moderate to High Likelihood of Clinical Diagnosis (95% Confidence Intervals) are Reported.
| Outcomes | T1 (n = 168) | T2 (n = 160) | T3 (n = 121) | T4 (n = 103) | T5 (n = 101) | T6 (n = 94) | T7 (n = 92) | T8 (n = 109) |
|
|---|---|---|---|---|---|---|---|---|---|
| Estimated Marginal Means (95% CI) from Linear Mixed Models | P value | ||||||||
|
| |||||||||
| Time-by-student status | 0.01 | ||||||||
| Student | 3.12 | 3.29 | 3.21 | 3.20 | 3.14 | 3.36 | 3.38 | 3.34 | |
| (2.75–3.48) | (2.97–3.62)a | (2.85–3.56) | (2.81–3.59) | (2.77–3.51)a | (2.98–3.74)a | (2.98–3.77)a | (2.96–3.72)a | ||
| Non-student | 3.65 | 3.15 | 3.31 | 3.47 | 2.93 | 2.77 | 2.74 | 2.76 | |
| (3.19–4.11) | (2.72–3.59)a | (2.82–3.8) | (2.98–3.96) | (2.38–3.48)a | (2.21–3.32)a | (2.19–3.29)a | (2.27–3.25)a | ||
| Time-by-birthplace | 0.03 | ||||||||
| Born in Canada | 3.29 | 3.16 | 3.13 | 3.27 | 3.01 | 3.16 | 3.12 | 3.29 | |
| (2.95–3.63) | (2.85–3.47) | (2.8–3.47) | (2.92–3.62) | (2.66–3.37) | (2.79–3.53) | (2.73–3.5) | (2.93–3.65) | ||
| Born Elsewhere | 3.31 | 3.76 | 3.88 | 3.42 | 3.50 | 3.33 | 3.50 | 2.51 | |
| (2.56–4.06) | (3.02–4.5) | (3.07–4.7) | (2.51–4.33) | (2.65–4.35) | (2.48–4.18) | (2.67–4.33) | (1.72–3.3) | ||
| Time-by-NEETb | 0.23 | ||||||||
| NEET | 3.85 | 3.13 | 3.4 | 3.55 | 3.02 | 3.06 | 2.97 | 2.57 | |
| (3.21–4.49) | (2.63–3.63) | (2.79–4) | (2.9–4.19) | (2.22–3.81) | (2.36–3.76) | (2.29–3.64) | (1.86–3.29) | ||
| In EETc | 3.18 | 3.28 | 3.20 | 3.23 | 3.10 | 3.21 | 3.22 | 3.22 | |
| (2.84–3.52) | (2.97–3.59) | (2.87–3.53) | (2.88–3.58) | (2.76–3.45) | (2.84–3.57) | (2.85–3.6) | (2.88–3.57) | ||
|
| |||||||||
| Time-by-student status | 0.01 | ||||||||
| Student | 1.76 | 2.15 | 2.01 | 1.67 | 2.19 | 2.34 | 2.31 | 2.30 | |
| (1.46–2.07) | (1.88–2.42) | (1.71–2.32) | (1.34–2.01) | (1.87–2.51)a | (2.01–2.68)a | (1.97–2.65) | (1.98–2.63) | ||
| Non-student | 2.00 | 1.85 | 2.07 | 2.17 | 1.61 | 1.70 | 1.89 | 2.06 | |
| (1.60–2.39) | (1.47–2.23) | (1.64–2.50) | (1.74–2.61) | (1.12–2.1)a | (1.21–2.2)a | (1.4–2.38) | (1.62–2.49) | ||
| Time-by-birthplace | 0.42 | ||||||||
| Born in Canada | 1.74 | 1.96 | 1.97 | 1.80 | 2.00 | 2.07 | 2.04 | 2.26 | |
| (1.46–2.01) | (1.71–2.21) | (1.69–2.25) | (1.51–2.1) | (1.69–2.3) | (1.76–2.39) | (1.71–2.36) | (1.96–2.56) | ||
| Born elsewhere | 2.45 | 2.58 | 2.36 | 2.04 | 2.2 | 2.59 | 2.86 | 2.16 | |
| (1.84–3.06) | (1.98–3.18) | (1.68–3.04) | (1.26–2.82) | (1.49–2.92) | (1.87–3.3) | (2.17–3.56) | (1.51–2.81) | ||
| Time-by-NEET | 0.04 | ||||||||
| NEET | 2.06 | 1.66 | 1.70 | 2.29 | 1.21 | 1.75 | 1.91 | 2.08 | |
| (1.49–2.63) | (1.22–2.11) | (1.16–2.25) | (1.71–2.87) | (0.48–1.93)a | (1.12–2.38) | (1.3–2.52) | (1.43–2.73) | ||
| In EET | 1.82 | 2.16 | 2.12 | 1.75 | 2.14 | 2.25 | 2.25 | 2.25 | |
| (1.54–2.09) | (1.91–2.42) | (1.84–2.4) | (1.44–2.05) | (1.85–2.44)a | (1.94–2.55) | (1.93–2.57) | (1.96–2.54) | ||
| Estimated Proportion of Participants with Moderate to High Likelihood of Clinical Diagnosis for Substance Use (95% CI) from Generalized Estimating Equations (GEE) models | P-value | ||||||||
|
| |||||||||
| Time-by-student status | 0.01 | ||||||||
| Student | 0.41 | 0.42 | 0.36 | 0.50 | 0.34 | 0.39 | 0.36 | 0.38 | |
| (0.31–0.52) | (0.32–0.53)a | (0.26–0.47) | (0.38–0.62) | (0.24–0.46) | (0.28–0.51)a | (0.25–0.49)a | (0.28–0.50)a | ||
| Non-student | 0.69 | 0.44 | 0.41 | 0.53 | 0.39 | 0.30 | 0.16 | 0.21 | |
| (0.51–0.82) | (0.31–0.58)a | (0.27–0.56) | (0.34–0.72) | (0.22–0.60) | (0.16–0.49)a | (0.08–0.29)a | (0.12–0.34)a | ||
| Time-by-birthplace | 0.33 | ||||||||
| Born in Canada | 0.47 | 0.40 | 0.36 | 0.48 | 0.37 | 0.37 | 0.27 | 0.33 | |
| (0.37–0.56) | (0.30–0.49) | (0.27–0.46) | (0.37–0.60) | (0.27–0.49) | (0.26–0.50) | (0.18–0.39) | (0.23–0.45) | ||
| Born elsewhere | 0.59 | 0.55 | 0.39 | 0.59 | 0.18 | 0.24 | 0.28 | 0.22 | |
| (0.41–0.75) | (0.34–0.74) | (0.18–0.65) | (0.31–0.82) | (0.05–0.48) | (0.08–0.53) | (0.09–0.61) | (0.07–0.50) | ||
| Time-by-NEET | 0.46 | ||||||||
| NEET | 0.68 | 0.42 | 0.34 | 0.45 | 0.49 | 0.23 | 0.16 | 0.29 | |
| (0.37–0.89) | (0.26–0.6) | (0.18–0.56) | (0.23–0.7) | (0.23–0.75) | (0.08–0.52) | (0.06–0.35) | (0.13–0.54) | ||
| In EET | 0.45 | 0.42 | 0.37 | 0.51 | 0.34 | 0.38 | 0.31 | 0.32 | |
| (0.36–0.55) | (0.33–0.52) | (0.27–0.47) | (0.40–0.63) | (0.25–0.44) | (0.27–0.49) | (0.21–0.43) | (0.23–0.43) | ||
Legend: Symbol a represents statistical significance for the pairwise contrasts between pandemic timepoints versus T1, symbol b represents Not in Education, Employment, or Training, and symbol c represents Education, Employment, or Training.
Notes: Each model used T1 as the reference group and adjusted for age and source cohort. P-values are reported for the time interaction. Data was collected from April 2018 to October 2019 (T1), April 2020 (T2), June 2020 (T3), August 2020 (T4), October 2020 (T5), December 2020 (T6), February 2021 (T7), and April 2021 (T8). The following formulas were used: (Non-Student EMM TX - Student EMM TX) - (Non-Student EMM T1 - Student EMM T1) for student status, (Born Elsewhere EMM TX - Born in Canada EMM TX) - (Born elsewhere EMM T1 - Born in Canada EMM T1) for birthplace, and (In EET EMM TX – Not in EET EMM TX) - (In EET EMM T1 – Not in EET EMM T1).
Figure 2.Line plot of internalizing, externalizing, and substance use scores for sociodemographic characteristics and time. Sociodemographic characteristics include student status, birthplace, and employment, education, or training status. Each model was adjusted for age and source cohort. Estimated Marginal Means are reported for internalizing and externalizing scores, and estimated proportion of participants with moderate to high likelihood of clinical diagnosis are reported for substance use scores. Error bars indicate the standard error.